Back to Search
Start Over
Immunotherapy in MMR-d/MSI-H recurrent/metastatic endometrial cancer.
- Source :
- Expert Review of Anticancer Therapy; Aug2024, Vol. 24 Issue 8, p717-729, 13p
- Publication Year :
- 2024
-
Abstract
- The advent of immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized the management of mismatch repair deficient (MMR-d)/microsatellite instability-high (MSI-H) endometrial cancer (EC). Initially investigated as monotherapy in phase I-II clinical trials for recurrent disease, immunotherapy demonstrated remarkable activity, yielding overall response rates (ORR) ranging from 27% to 58%. Based on these promising findings, phase III trials have explored the integration of immunotherapy into first-line treatment regimens for advanced/recurrent EC in combination with chemotherapy or other agents such as tyrosine kinase inhibitors (TKIs), resulting in improved ORR, progression-free survival, and overall survival compared to the standard chemotherapy regimen of paclitaxel and carboplatin. As a result, the incorporation of ICIs with standard platinum-based chemotherapy is becoming a new standard of care in MMR-d/MSI-H EC. This review synthesizes literature from PubMed, Embase databases, and recent congress abstracts on gynecological cancers. It covers MMR-d/MSI-H EC incidence, molecular diagnostics, clinical trial outcomes, predictive biomarkers for ICIs, patient profiles likely to benefit, resistance mechanisms, and the future of immunotherapy in this setting. By offering a comprehensive overview, this review delineates the pivotal role of ICIs in the management of MMR-d/MSI-H EC. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 14737140
- Volume :
- 24
- Issue :
- 8
- Database :
- Complementary Index
- Journal :
- Expert Review of Anticancer Therapy
- Publication Type :
- Academic Journal
- Accession number :
- 178650901
- Full Text :
- https://doi.org/10.1080/14737140.2024.2367472